New bacteria causing diseases of poultry and vaccine produced from them

FIELD: biotechnologies.

SUBSTANCE: new strain of bacteria Pasteurella trehalosi is proposed, where the specified bacteria are positive in respect to beta-haemolysis, positive in respect to oxidase, positive in respect to catalase, negative in respect to urease, positive in respect to nitrates, negative in respect to indole, MacConkey-positive, positive in respect to glucose, positive in respect to saccharose, positive in respect to mannitol, negative in respect to arabinose, negative in respect to cellobiose, positive in respect to xylose, negative in respect to salicin, negative in respect to ornithine, negative in respect to esculin, negative in respect to alpha-fucosidase, positive in respect to beta-galactosidase. Also the strain of bacteria Mannheimia haemolytica is proposed. These bacteria are deposited under registration numbers ATCC No. PTA-3667, ATCC No. PTA-3668, ATCC No. PTA-3669.

EFFECT: immunisation of chickens with the purpose to prevent disease caused by above bacteria.

7 cl, 22 dwg, 2 tbl, 6 ex

 

The text descriptions are given in facsimile form.

1. The strain selected gram-negative, pleomorphic shaped sticks of bacterial pathogens of the upper respiratory tract and the genital tract in chickens to obtain a vaccine against the infection, which is caused by these bacteria, where the bacteria is Pasteurella trehalosi and these bacteria are positive in relation to beta-hemolysis, positive regard oxidase positive in relation to the katal is SHL, negative against urease, positive in relation to nitrate, negative in relation to indole, MacConkey-positive, positive in relation to glucose, positive in relation to sucrose, positive in respect of mannitol, negative in respect of arabinose negative in relation to cellobiose, positive in respect of xylose, negative in respect of salicin, negative in respect of ornithine, negative in respect of esculin, negative in relation to alpha fucosidase, positive in relation to beta-galactosidase.

2. The bacterial strain according to claim 1, where these bacteria are positive in respect of trehalose.

3. The bacterial strain according to claim 2, where these bacteria are deposited under the registration number of ATSS No. PTA-3667.

4. The bacterial strain according to claim 2, where these bacteria are deposited under the registration number of ATSS No. PTA-3668.

5. The strain selected gram-negative, pleomorphic shaped sticks of bacterial pathogens of the upper respiratory tract and the genital tract in chickens to obtain a vaccine against the infection, which is caused by these bacteria, where the bacteria is Mannheimia haemolytica and where these bacteria are positive in relation to beta-hemolysis, positive regard oxidase positive regarding catalase negative against urease, positive in relation to nitrate, negative in respect of the indole, MacConkey-positive, positive in relation to glucose, positive in relation to sucrose, positive in respect of mannitol, negative in respect of arabinose negative in relation to cellobiose, positive in respect of xylose, negative in respect of salicin, negative in respect of ornithine, negative in respect of esculin, negative in relation to alpha fucosidase, positive in relation to beta-galactosidase.

6. The bacterial strain according to claim 5, where these bacteria are negative in relation to trehalose.

7. The bacterial strain according to claim 6, where these bacteria are deposited under the registration number of ATSS No. PTA-3669.



 

Same patents:

FIELD: biotechnologies.

SUBSTANCE: nutrient medium contains monosubstituted potassium phosphate, magnesium sulphate, sodium phosphate, iron citrate, glycocol, monosubstituted sodium glutamate, glycerine, agar, potato broth, whey of cattle and distilled water at specified ratios.

EFFECT: invention makes it possible to increase yield of biomass of L-forms of mycobacteria and to reduce time of biomass accumulation.

1 tbl

FIELD: food industry.

SUBSTANCE: invention relates to food industry, in particular to production of food additives based on sea weeds. The method for production of a functional food additive (being a source of food fibres, bioactive polysaccharides, iodine-containing substances, a combination of ω-3 ω-6 polyunsaturated fatty acids) envisages sea weeds treatment. The milled sea weeds are maintained in water at a ratio of 1:10 at a temperature of 20-25°C during 20-40 minutes for swelling. Then one introduces probiotic microorganisms i.e. Lactobacillus genius lactic acid bacteria into the produced jelly-like sea weed substrate at t=20-25°C during 12-24 hours till concentration is equal to no less than 107 CFU/g to accrete biomass. The invention allows to produce a functional food additive based on sea weeds and having a complex preventive and probiotic action. The produced additive is used in the recipe of mince meat products in an amount of 5% of the raw material weight.

EFFECT: invention promotes semi-products quality enhancement, structure and appearance improvement and storage life extension.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and concerns oligonucleotide primers for B.mallei genetic typing. The presented primers are complementary to a differentiation fragment BMA0416 of an equinia agent genome, possess activity of upstream and downstream primers in an amplification reaction and have the following structure: 5'-TGGCGGAGTATGGATGCTG-3' - BmVAT6-Ch2s 5'-GAACGAGAACACCTACGACCTGAT-3' - BmVAT6-Ch2as.

EFFECT: presented invention may be used in practical healthcare for detection of the differentiation DNA fragment BMA0416 of the equinia agent.

3 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and concerns oligonucleotide primers for B.mallei genetic typing. The presented primers are complementary to a differentiation fragment BMA0577 of an equinia agent genome, possess activity of upstream and downstream primers in an amplification reaction and have the following structure: 5' - GAG GAT GAA GGT GCC GTG G - 3' - BmVATl-Chls 5' - GAC AAC TAC TTC ATC GGC TAT CTG - Y - BmVATl-Chlas.

EFFECT: presented invention may be used in practical healthcare for detection of the differentiation DNA fragment BMA0577 of the equinia agent.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. Described is a plasmid which codes esterase Psychrobacter cryohalolentis K5T and contains Ndel/Xhol - a DNA fragment of plasmid pET32a with length of 5.366 thousand base pairs, which includes a promoter of bacteriophage T7, a translation enhancer of gene 10 of the bacteriophage T7, a transcription terminator of the bacteriophage T7, a bla β-lactamase gene which determines resistance of cells transformed by plasmid pPC023 to ampicillin, a replication initiation section ori; and Ndel/Sall - a DNA fragment with size of 0.869 thousand base pairs, which contains a gene which codes the mature form of esterase Psychrobacter cryohalolentis K5T with an amino acid sequence SEQ ID NO: 2, given in the description, having an C-end hexahestidine linker. Provided is an Escherichia coli bacteria strain which is modified by said plasmid, a producer of a polypeptide having esterase Psychrobacter cryohalolentis K5T activity.

EFFECT: invention increases the level of biosynthesis of esterase to 20% of total cell protein.

2 cl, 2 dwg, 5 ex

FIELD: agriculture.

SUBSTANCE: biological preparation for stimulation of growth and protection of plants from diseases, increase in productivity and soil fertility contains biomass Bacillus amyloliquefaciens RNCIM B-11008 and humates at the following ratio of components in vol. %: biomass Bacillus amyloliquefaciens RNCIM B-11008 - vegetative cells and spores of 1.24-1.30×1010 CFU/ml of culture fluid and the spore content 94% of the total amount of CFU - 99.0, humates - 1.0.

EFFECT: biological preparation enables to protect plants from fungal and bacterial diseases, to improve the phytosanitary condition of soil and improve its fertility, to increase crop yields and improve the quality of agricultural products.

5 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The symbiontic strain of Corynebacterium diphtheriae tox " No.108 is isolated from a bacteria carrier - a tonsillitis patient at IKB No.1 Moscow. The strain is harmless, non-reactogenic, does not possess allergic properties, antigens of which increase resistance of the microorganism to infectious diseases. The strain of Corynebacterium diphtheriae tox" No.108 is deposited in the National Collection of Normal Microflora of the G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 381.

EFFECT: invention enables to create non-specific resistance of farm animals to infectious bacterial and viral diseases.

4 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microbiology and biotechnology and can be used in food industry and medicine. The microbial strain of Lactobacillus plantarum Tensia DSM 21380 produces conjugated linoleic acid (CLA), hydrogen peroxide (H2O2), nitrogen monoxide (NO), contains plantaricin encoding genes and has antioxidant activity. This strain and its liophilised form are used to prepare an antimicrobial and hypotensive probiotic, a dairy product and a medicinal agent which lowers blood pressure. The strain and its liophilised form are also used to increase polyamine turnover in the body, to attain a dominant position among intestinal lactic bacteria in the gastrointestinal tract and to prolong the shelf life of a dairy product.

EFFECT: use of the invention enables to lower blood pressure, suppress undesirable microflora and inhibit oxidative processes.

12 cl, 8 dwg, 31 tbl, 7 ex

FIELD: agriculture.

SUBSTANCE: method to stimulate growth and to protect small-fruit crops against diseases caused fungic pathogens includes treatment of plants with a biopreparation in a liquid form by soaking roots of seedlings prior to planting, or their sprinkling after planting, or sprinkling of plants in the period of vegetation and fruiting, or sprinkling of soil around plants with its further soaking with water. The biopreparation is a mixture of strains of bacteria B. subtilis VKPM B-10641, B. amyloliquefaciens VLPM B-10642, B. licheniformis VKPM B-10561 and B. licheniformis VKPM B-10562 or a mixture of strains of bacteria B. subtilis VKPM B-10641, B. amyloliquefaciens VKPM B-10642 and B. licheniformis VKPM B-10562 with a titre of each strain of not less than 105 CFU/ml in the form of a water suspension.

EFFECT: invention provides for higher protection of small-fruit crops against diseases caused by fungic pathogens, due to use of a mixture of strains of different types of bacteria of Bacillus type, having higher antagonistic activity, and also provision of the possibility of stimulation of growth of small-fruit crops.

5 cl, 10 tbl, 8 ex

FIELD: biotechnologies.

SUBSTANCE: strain Enterococcus hirae BC - 37 having high antagonistic activity is deposited in the Russian National Collection of Industrial Microorganisms (RNCIM) under the registration number VKPMV-10090 and may be used, for instance, in production of such cultured milk foods as kefir, cottage cheese or ryazhenka.

EFFECT: invention makes it possible to produce a strain having high antagonistic activity and high speed of milk turning sour.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new glycopeptide antibiotic derivative of formula (IV-1), a method for preparing it, and to intermediate compounds for preparing it.

EFFECT: glycopeptide derivative has antibacterial activity on a vancomycin-resistant bacterium.

14 cl, 51 tbl, 121 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for treating and preventing viral and bacterial infections, containing as active ingredients: lysocyme, peroxidase, poviargol, as anti-inflammatory ingredients: escin and glycyrrhizic acid or a salt thereof, as carriers - liposome based on high-active hydrogenated lecithins in a combination with cholesterol and pharmaceutically acceptable carriers and excipients, and the ingredients of the composition are taken in a certain ratio, wt %.

EFFECT: invention ensures maintaining prolonged activity of the enzymes being the ingredients of the composition, fast skin penetration and absorption.

4 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds - substituted 1,3-diethyl-8-vinyl-7-methyl-3,7-dihydropurine-2,6-diones of general formula 1, which exhibit antagonist activity on adenosine A2A receptors. The compounds can be used as an active source of a medicinal agent or adjuvant for pharmaceutical compositions and medicinal agents. The invention also relates to a method of inhibiting and a method of treating diseases of the central nervous system, oncological, viral and bacterial diseases which are mediated by adenosine A2a receptor activity. In general formula 1 , where: Ar is 2,5-dimethoxyphenyl, 4-isobutoxy-3-methoxyphenyl, 3-phenoxyphenyl substituted with pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, C1-C5alkoxy group, amino group, optionally substituted with a mono- or di-C1-C5alkyl; 3-methylthiophen-2-yl, pyrazol-4-yl, substituted with C1-C5alkyl; 2,3-dihydro-benzo[1,4]dioxin-6-yl, optionally substituted with C1-C5alkoxycarbonyl, carbamoyl, which is optionally substituted with mono- or di-C1-C5alkyl, or carbonyl-piperazine, optionally substituted with C1-C5alkyl.

EFFECT: improved properties.

13 cl

Antibacterial agent // 2480239

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology of bacteriophagues. An antibacterial agent contains a bacteriophage concentrate, any preserving agent, except for those related to quaternary ammonium derivatives, heavy metal derivatives, oxidising agents, bromine or iodine-containing, formaldehyde-releasing preserving agents, water, a gelling agent in the form of a non-ionic or anionic high-molecular compound, a non-ionic surfactant and a pH adjustor in the following ratio, wt %: bacteriophage concentrate of Appelman's lytic activity min. 10-4 for each type of bacteriophague - 0.001-10.0; gelling agent - 0.05-15.0; surfactant - 0.001-2.0; preserving agent - 0.05-0.6; pH adjustor to 6.0-8.0; water up to 100.0.

EFFECT: extended range of products containing bacteriophages as a basic active ingredient, provided biological stability and activity of bacteriophages in the composition of the product; the composition possess a low risk of toxicity and side effects, provides storage stability and efficacy within the wide range of temperatures.

11 cl, 15 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of medicine. Antibacterial composition on the basis of colloid silver, stabilised with citric acid or its salts, suspended in water, contains, at least, one cation surface active agent. Antibacterial composition is obtained by mixing. Water solution of silver salt, solution of, at least, one stabilising agent, and reducing agent solution, with intensive mixing of mixture and further addition of solution of, at least one cation surface active agent to obtained mixture.

EFFECT: ensured is antibacterial activity with lower concentration of ingredients.

13 cl, 1 tbl, 1 dwg, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds: 4-(1-cyclohepta-2,4,6-trienyl)aniline of formula I and chloride thereof of formula II . The compounds have antimicrobial activity towards a range of opportunistic pathogens: Staphylococcus aureus, Staphylococcus epidermis. Staphylococcus saprophytics, Escherichia coli and Candida albicans, as well as yeast-like fungi Candida albicans.

EFFECT: compounds have activity which is considerably higher than that of existing analogues in terms of antimicrobial action, as well as activity of the existing analogue which is closest in terms of structure with respect to yeast-like fungi Candida albicans.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new forms of compounds of formula I possessing broad-spectrum antibiotic activity, especially crystalline polymorphous forms of such compounds, also in the form of a hydrate or a solvate, particularly crystalline polymorph of tiacumicin. The invention also refers to compositions containing such crystalline polymorphous compounds, methods for preparing and using them.

EFFECT: there are presented pharmaceutical compositions possessing antibiotic activity, containing crystalline polymorphs in a therapeutically effective amount and a pharmaceutically acceptable excipient.

26 cl, 5 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses a number of polynucleotides and polypeptides β-hemolytic streptococci, in particular polypeptides and polynucleotides of Streptococcus pyogenes, and based on them immunogenic compositions, used for prevention or reduction of symptoms of colonisation or infection, caused by β-hemolytic streptococci. Immunogenic composition (versions) contains mixture of two or more polypeptides, encoded by sequence of nucleic acid (NA), which has, at least, 90% identity of sequence of NA, selected from group, consisting of peptidase C5a (SCP), open reading frame (OPC)554, OPC 1218, OPC 1358 and OPC 2459. One of versions of immunogenic composition contains polypeptide SCP, polypeptide peptidylpropylisomerase and, at least, one other polypeptide. Also disclosed are methods of protecting susceptible mammal against colonisation or infection, caused by β-hemolytic streptococcus, by immunisation of immunogenic composition by invention.

EFFECT: invention provides immunogenic compositions and methods for prevention or reduction of symptoms of infections, caused by β-hemolytic streptococci of group A, B, C and G, as well as ensures immunity to wide spectrum of bacteria BHS.

41 cl, 16 dwg, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and medicine and deals with method of treating formation of biofilms P. Aeruginosa in patient or method of treating chronic infection P. Aeruginosa in patient by introduction of combination, including (a) 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or its pharmaceutically acceptable salt and (b) antibiotic, selected from group, including gentamicin, amikacin, tobramycin, ciprofloxacin, levofloxacin, cefrazidime, cefepime, cefpirome, piperacillin, ticarcillin, meropenem, imipenem, polymyxin B, colistin and azreonam.

EFFECT: method ensures high treatment efficiency.

10 cl, 5 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to vaginal gel with immunomodulating activity, which as active substance contains immunomodulator -5.0 wt % of oxymethyluracyl, and as base contains sodium salt of carboxymethylcellulose, propylene glycol, Kollidon VA 64 and water, and as preservative contains nipagin and nipazol in ratio 1:1.

EFFECT: claimed immunomodelling vaginal gel possesses expressed adhesive properties, high pharmaceutical availability, convenience in dosing and application.

1 dwg, 16 ex

FIELD: medicine.

SUBSTANCE: Mycoplasma bacterium shows expression lower at least by 25% of one or more one protein specified in a group consisting of piruvate dehydrogenase, enolase, 2-desoxyribose-5-phosphataldolase and ribosomal protein L35. The vaccine containing such strain is applicable for animal vaccination against an infection caused by Mycoplasma bacteria. A method for identifying clones of such bacterium involves: placing an initial population of Mycoplasma bacterium into the attenuation environment to produce a potentially attenuated bacterial population; analysis of separate clones of the potentially attenuated bacterial population in relation to low expression of one or more said proteins; and testing the clones identified as having expression lower at least by 25% of one or more proteins in relation to virulence.

EFFECT: invention enables developing an attenuation strategy of Mycoplasma bacteria and may be used for prevention of the diseases caused by such bacterium.

16 cl, 1 dwg, 5 tbl, 3 ex

Up!